Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.43
+0.0000
Post-market: 8.450.0200+0.24%19:55 EST
Volume:7.02M
Turnover:59.13M
Market Cap:758.16M
PE:-8.98
High:8.44
Open:8.42
Low:8.42
Close:8.43
Loading ...

3 Promising Penny Stocks With Market Caps Under $2B In US

Simply Wall St.
·
11 Dec 2024

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
11 Dec 2024

Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy

GuruFocus.com
·
11 Dec 2024

Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor

MT Newswires Live
·
11 Dec 2024

Chimerix price target raised to $7 from $5 at JonesResearch

TIPRANKS
·
11 Dec 2024

Dow Falls 150 Points; Oracle Posts Downbeat Results

Benzinga
·
10 Dec 2024

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

Benzinga
·
10 Dec 2024

Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket

MT Newswires Live
·
10 Dec 2024

Chimerix Shares Double Premarket on Potential for Dordaviprone Approval in Q3 Following 'Extensive' Discussions With FDA

MT Newswires Live
·
10 Dec 2024

24H | Chimerix Shares Soar 173% as Company Plans FDA Submission of Cancer Drug Dordaviprone

Dow Jones
·
10 Dec 2024

BUZZ-Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug

Reuters
·
10 Dec 2024

Chimerix to submit dordaviprone NDA to FDA, seeks accelerated approval

TIPRANKS
·
10 Dec 2024

BRIEF-Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End

Reuters
·
10 Dec 2024

Chimerix Inc - Potential Approval for Dordaviprone in Q3 2025

THOMSON REUTERS
·
10 Dec 2024

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End

THOMSON REUTERS
·
10 Dec 2024

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

GlobeNewswire
·
10 Dec 2024